Quantcast

Novartis To Initiate Proof Of Concept Study With Cosentyx - Quick Facts


Shutterstock photo


(RTTNews.com) - Novartis ( NVS ) announced the plan to initiate ARROW, a head-to-head proof of concept study to assess the mechanistic superiority of the direct inhibition of IL-17A with Cosentyx (secukinumab) over the inhibition of IL-23 with Tremfya (guselkumab) in patients with psoriatic plaques resistant to treatment with Stelara. Study results are expected in 2019.

Cosentyx is the first fully-human biologic that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriasis, ankylosing spondylitis, and psoriatic arthritis.


Read the original article on RTTNews (http://www.rttnews.com/2895030/novartis-to-initiate-proof-of-concept-study-with-cosentyx-quick-facts.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: Politics , World Markets , Stocks , Economy , Commodities
Referenced Symbols: NVS


More from RTT News

Subscribe






See All RTT news









Research Brokers before you trade

Want to trade FX?